3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
2
Uterine Cervical Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rectal Neoplasms
1
Rectal Diseases
1
Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Brenner Tumor
1
Interventions
Sorafenib
5
Nivolumab
3
lenvatinib
2
cabozantinib
2
Ipilimumab
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
atezolizumab
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Carcinoma, Hepatocellular
×
Bevacizumab
×
Clear all
NCT03434379
2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3
Completed
558 enrolled
48 charts
1 FDA